GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Infant Bacterial Therapeutics AB (OSTO:IBT B) » Definitions » Change In Other Working Capital

Infant Bacterial Therapeutics AB (OSTO:IBT B) Change In Other Working Capital : kr-17.15 Mil (TTM As of Mar. 2025)


View and export this data going back to 2016. Start your Free Trial

What is Infant Bacterial Therapeutics AB Change In Other Working Capital?

Infant Bacterial Therapeutics AB's Change In Other Working Capital for the quarter that ended in Mar. 2025 was kr-14.91 Mil. It means Infant Bacterial Therapeutics AB's Other Working Capital declined by kr14.91 Mil from Dec. 2024 to Mar. 2025 .

Infant Bacterial Therapeutics AB's Change In Other Working Capital for the fiscal year that ended in Dec. 2024 was kr23.12 Mil. It means Infant Bacterial Therapeutics AB's Other Working Capital increased by kr23.12 Mil from Dec. 2023 to Dec. 2024 .


Infant Bacterial Therapeutics AB Change In Other Working Capital Historical Data

The historical data trend for Infant Bacterial Therapeutics AB's Change In Other Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Infant Bacterial Therapeutics AB Change In Other Working Capital Chart

Infant Bacterial Therapeutics AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Change In Other Working Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.29 3.06 4.69 28.27 23.12

Infant Bacterial Therapeutics AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Change In Other Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.36 -11.77 -24.49 34.03 -14.91

Infant Bacterial Therapeutics AB Change In Other Working Capital Calculation

Change In Other Working Capital is any increase or decrease between periods of other working capital that are not otherwise classified.

Change In Other Working Capital for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-17.15 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Infant Bacterial Therapeutics AB Change In Other Working Capital Related Terms

Thank you for viewing the detailed overview of Infant Bacterial Therapeutics AB's Change In Other Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Infant Bacterial Therapeutics AB Business Description

Traded in Other Exchanges
Address
Bryggargatan 10, Stockholm, SWE, 111 21
Infant Bacterial Therapeutics AB is a pharmaceutical company. Its purpose is to develop and commercialize drugs for diseases affecting premature babies. Its focus is on the drug candidate IBP-9414, whose development program is designed to show a reduced incidence of necrotizing enterocolitis (NEC) and improved gastrointestinal function (SFT) when treated with IBP-9414's active substance Lactobacillus reuteri bacterial strain naturally found in human breast milk. Its portfolio also includes additional drug candidates, IBP-1016, IBP-1118 and IBP-1122. IBP1016, for the treatment of gastroschisis, is a life-threatening and rare disorder in which children are born with externalized gastrointestinal organs.

Infant Bacterial Therapeutics AB Headlines

No Headlines